Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker

Wieczorek, Andreas J.; Sitaramam, Vetury; Machleidt, Werner; Rhyner, Kaspar; Perruchoud, André P.; Block, Lutz H.

Article navigation

Articles| December 01 1987

Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker^¹

Andreas J. Wieczorek;

Andreas J. Wieczorek

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Vetury Sitaramam;

Vetury Sitaramam

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Werner Machleidt;

Werner Machleidt

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Kaspar Rhyner;

Kaspar Rhyner

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

André P. Perruchoud;

André P. Perruchoud

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Lutz H. Block

Department of Medicine, University of Zurich

,

CH-8091 Zurich, Switzerland [A. J. W., K. R.]

;

Indian Council of Medical Research, Jamai Osmania P. O.

,

Hyderabad 500007, India [V. S.]

;

Institute of Physiological Chemistry, University of Munich

,

D-8000 Munich, Federal Republic

of

Germany

[W. M.]; and

Department of Medicine, University Hospital of Basel

,

Petersgraben 4, CH-4031 Basel

,

Switzerland

[A. P. P., L. H. B.]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

²

To whom requests for reprints should be addressed.

Received: December 15 1986

Revision Received: June 19 1987

Accepted: August 24 1987

Online ISSN: 1538-7445

Print ISSN: 0008-5472

1987

Cancer Research, Inc.

Cancer Res (1987) 47 (23): 6407–6412.

Abstract

The circulating level of a novel RNA-proteolipid complex associated with malignant diseases was critically evaluated as a tumor marker in clinical oncology. The complex, isolated from the sera of cancer patients, exhibited unvarying chemical composition regardless of the cell type and clinical staging. Clearance from blood was rapid with a half-life of approximately 2 days. Tumor mass could be correlated with the circulating level. After effective treatment the level fell and rose again 10 months prior to the conventional clinical diagnosis of relapse.

¹

Supported by the Krebsliga of the Kautou Zürich, Switzerland.

This content is only available via PDF.

1987

Cancer Research, Inc.

Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker^¹

Abstract

Citing articles via

Email alerts

AACR Journals

Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker1

Abstract

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker^¹